Skip to main content
Midas Edge

Kiniksa Pharmaceuticals International, plc

For the period ended Jun 30, 2025. Filed Jul 29, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 29, 2025

KNSA$98.76+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

​ · ​ · ​ · Incorporated by Reference
ExhibitNumber · Exhibit Description · Form · File No. · Exhibit · FilingDate · Filed/FurnishedHerewith
​​​​​​​​​​​​​
10.1#†​KPL-387 Long-Term Incentive Plan for Executive Officers​8-K​001-38492​10.1​4/23/2025​​
​​​​​​​​​​​​​
10.2#​Form of Milestone 1 Cash Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan​8-K​001-38492​10.2​4/23/2025​​
​​​​​​​​​​​​​
10.3#​Form of Milestone 2 Cash Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan​8-K​001-38492​10.3​4/23/2025​​
​​​​​​​​​​​​​
10.4#​Form of Milestone 1 PSU Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan​8-K​001-38492​10.4​4/23/2025​​
​​​​​​​​​​​​​
10.5#​Form of Milestone 2 PSU Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan​8-K​001-38492​10.5​4/23/2025​​
​​​​​​​​​​​​​
10.6#​Form of Milestone 1 Option Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan​8-K​001-38492​10.6​4/23/2025​​
​​​​​​​​​​​​​
10.7#​Form of Milestone 2 Option Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan​8-K​001-38492​10.7​4/23/2025​​
​​​​​​​​​​​​​
10.8#​Consulting Agreement by and between Kiniksa Pharmaceuticals International, plc and Dr. Richard Levy​​​​​​​​​*
​​​​​​​​​​​​​
10.9#​2018 Incentive Award Plan and forms of award agreements thereunder, as amended​​​​​​​​​*
​​​​​​​​​​​​​
31.1​Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer​​​​​​​​​*
​​​​​​​​​​​​​
31.2​Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer​​​​​​​​​*
​​​​​​​​​​​​​
32.1​Section 1350 Certification of Chief Executive Officer​​​​​​​​​**
​​​​​​​​​​​​​
32.2​Section 1350 Certification of Chief Financial Officer​​​​​​​​​**
​​​​​​​​​​​​​
​​​Incorporated by Reference
ExhibitNumberExhibit DescriptionFormFile No.ExhibitFilingDateFiled/FurnishedHerewith
101.INS​XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document​​​​​​​​​***
​​​​​​​​​​​​​
101.SCH​Inline XBRL Taxonomy Extension Schema Document​​​​​​​​​***
​​​​​​​​​​​​​
101.CAL​Inline XBRL Taxonomy Extension Calculation Linkbase Document​​​​​​​​​***
​​​​​​​​​​​​​
101.DEF​Inline XBRL Extension Definition Linkbase Document​​​​​​​​​***
​​​​​​​​​​​​​
101.LAB​Inline XBRL Taxonomy Label Linkbase Document​​​​​​​​​***
​​​​​​​​​​​​​
101.PRE​Inline XBRL Taxonomy Extension Presentation Linkbase Document​​​​​​​​​***
​​​​​​​​​​​​​
104​Cover page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document​​​​​​​​​***
#Indicates management contract or compensatory plan
†Portions of the exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv)
*Filed herewith
**Furnished herewith
***Submitted electronically herewith
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.